[go: up one dir, main page]

PT1336621E - Respostas imunitarias contra antigenios dos vph, suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector de expressao com aptidao para a expressao destas proteinas - Google Patents

Respostas imunitarias contra antigenios dos vph, suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector de expressao com aptidao para a expressao destas proteinas

Info

Publication number
PT1336621E
PT1336621E PT03001726T PT03001726T PT1336621E PT 1336621 E PT1336621 E PT 1336621E PT 03001726 T PT03001726 T PT 03001726T PT 03001726 T PT03001726 T PT 03001726T PT 1336621 E PT1336621 E PT 1336621E
Authority
PT
Portugal
Prior art keywords
hpv
cells
antigen
stress protein
expression
Prior art date
Application number
PT03001726T
Other languages
English (en)
Inventor
Randall Chu
Original Assignee
Stressgen Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21993829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1336621(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stressgen Biotechnologies Corp filed Critical Stressgen Biotechnologies Corp
Publication of PT1336621E publication Critical patent/PT1336621E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT03001726T 1997-08-05 1998-03-20 Respostas imunitarias contra antigenios dos vph, suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector de expressao com aptidao para a expressao destas proteinas PT1336621E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5483597P 1997-08-05 1997-08-05

Publications (1)

Publication Number Publication Date
PT1336621E true PT1336621E (pt) 2006-08-31

Family

ID=21993829

Family Applications (2)

Application Number Title Priority Date Filing Date
PT03001726T PT1336621E (pt) 1997-08-05 1998-03-20 Respostas imunitarias contra antigenios dos vph, suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector de expressao com aptidao para a expressao destas proteinas
PT98910557T PT1002110E (pt) 1997-08-05 1998-03-20 Respostas imunitarias contra antigenios dos vph suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector deexpressao com aptidao para a expressao destas proteinas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT98910557T PT1002110E (pt) 1997-08-05 1998-03-20 Respostas imunitarias contra antigenios dos vph suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector deexpressao com aptidao para a expressao destas proteinas

Country Status (19)

Country Link
US (4) US6524825B1 (pt)
EP (1) EP1002110B2 (pt)
JP (2) JP4198315B2 (pt)
KR (2) KR100843109B1 (pt)
CN (3) CN100489105C (pt)
AT (2) ATE327259T1 (pt)
AU (1) AU6492498A (pt)
BR (1) BR9812272A (pt)
CA (1) CA2298840A1 (pt)
DE (2) DE69834671T2 (pt)
DK (1) DK1002110T3 (pt)
ES (2) ES2266652T3 (pt)
HK (2) HK1028981A1 (pt)
HU (1) HUP0003601A3 (pt)
IL (1) IL134341A0 (pt)
NZ (3) NZ538399A (pt)
PL (1) PL196805B1 (pt)
PT (2) PT1336621E (pt)
WO (1) WO1999007860A1 (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164298A1 (en) 1993-06-04 1994-12-22 Richard A. Young Stress proteins and uses therefor
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
PT1336621E (pt) * 1997-08-05 2006-08-31 Stressgen Biotechnologies Corp Respostas imunitarias contra antigenios dos vph, suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector de expressao com aptidao para a expressao destas proteinas
EP1196772A2 (en) 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
US20050244434A1 (en) * 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
AUPQ233799A0 (en) * 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
AU7743100A (en) * 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
WO2001029233A2 (en) * 1999-10-20 2001-04-26 The Johns Hopkins University School Of Medicine Chimeric immunogenic compositions and nucleic acids encoding them
CA2396384A1 (en) * 2000-01-14 2001-07-19 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
AU2001261515A1 (en) * 2000-05-12 2001-11-26 The Regents Of The University Of California Treatment of human papillomavirus (hpv)-infected cells
CA2413543A1 (en) * 2000-06-26 2002-01-03 Stressgen Biotechnologies Corporation Human papilloma virus treatment
WO2002012281A2 (en) 2000-08-03 2002-02-14 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
EP1363660A4 (en) * 2001-02-01 2006-06-21 Univ Johns Hopkins HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN
AU2002247084B2 (en) 2001-02-05 2007-01-04 Nventa Biopharmaceuticals Corporation Hepatitis B virus treatment
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
KR100785397B1 (ko) * 2001-06-28 2007-12-13 아피메즈 주식회사 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
KR100474114B1 (ko) * 2001-12-24 2005-03-08 대한민국 소 타일레리아병에 대한 면역원성이 증진된 융합단백질, 및 그의 제조방법 및 용도
US7763259B2 (en) * 2003-01-10 2010-07-27 The Regents Of The University Of Colorado Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
US7211257B2 (en) * 2003-02-10 2007-05-01 Rosalind Franklin University Of Medicine And Science Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
EP1664322B1 (en) 2003-05-22 2013-07-10 Fraunhofer USA, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
JP2007505147A (ja) 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
US7304139B2 (en) * 2003-10-28 2007-12-04 University Of Florida Research Foundation, Inc. Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same
US7927580B2 (en) * 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
FR2868781B1 (fr) * 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
CN1727362B (zh) * 2004-07-30 2010-12-01 中国人民解放军第二军医大学 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用
CN1769298B (zh) * 2004-11-05 2010-04-07 中国人民解放军军事医学科学院生物工程研究所 一种具有抗肿瘤作用的融合蛋白及其编码基因与应用
CA2594040A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
CN1299769C (zh) * 2005-01-31 2007-02-14 中国医学科学院肿瘤医院肿瘤研究所 人乳头瘤病毒和热休克蛋白重组蛋白疫苗及其用途
DE602006021408D1 (de) * 2005-04-27 2011-06-01 Univ Leiden Medical Ct Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
CA2616859C (en) 2005-08-03 2015-04-14 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7622121B2 (en) * 2005-09-21 2009-11-24 New York University Heat shock proteins from Mycobacterium leprae and uses thereof
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
AU2007215082B2 (en) * 2006-02-13 2012-07-12 Ibio, Inc. HPV antigens, vaccine compositions, and related methods
US8124103B2 (en) 2006-02-13 2012-02-28 Fraunhofer Usa, Inc Influenza antigens, vaccine compositions, and related methods
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
ZA200810740B (en) * 2006-05-31 2010-06-30 Nventa Biopharmaceuticals Corp Bioactive purified HspE7 compositions
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
US8859218B2 (en) * 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
AR064500A1 (es) * 2006-12-22 2009-04-08 Dow Agrosciences Llc Vacunas del virus west nile (wnv) de plantas, vectores y secuencias optimizadas de codones de plantas
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080311145A1 (en) * 2007-04-04 2008-12-18 Specigen, Inc. Protein cage immunotherapeutics
WO2008134643A2 (en) * 2007-04-28 2008-11-06 Fraunhofer Usa, Inc. Trypanosoma antigens, vaccine compositions, and related methods
US8088392B2 (en) * 2007-06-18 2012-01-03 Yunxu Cao Capsid proteins and uses therefore
CA2691091C (en) * 2007-06-18 2013-07-30 Shanghai Zerun-Ankegens Biopharmaceutical Co., Ltd Fusion protein, macromolecule assembled from the fusion protein, and its use in the prevention or treatment of human papillomavirus related diseases
CA2692933C (en) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
CU23674A1 (es) 2007-07-31 2011-05-27 Ct Ingenieria Genetica Biotech Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica
BRPI0815662A2 (pt) * 2007-08-20 2016-09-27 Fraunhofer Usa Inc vacinas, antígenos, composições, e métodos profilácticos e terapêuticos para gripe
US20110110979A1 (en) * 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
WO2009129502A2 (en) * 2008-04-18 2009-10-22 The General Hospital Corporation Immunotherapies employing self-assembling vaccines
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
US8530431B2 (en) 2009-03-23 2013-09-10 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
JP2012526286A (ja) 2009-05-07 2012-10-25 オンコヘルス コーポレーション ヒトパピローマウイルス（ｈｐｖ）およびｈｐｖ関連癌の初期段階および後期段階の検出、スクリーニング、および診断のための高度または≧ｃｉｎ２の同定
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
WO2011084598A1 (en) 2010-01-08 2011-07-14 Oncohealth Corporation High throughput cell-based hpv immunoassays for diagnosis and screening of hpv-associated cancers
US8853149B2 (en) 2010-03-19 2014-10-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Integrin interaction inhibitors for the treatment of cancer
WO2012145509A2 (en) 2011-04-19 2012-10-26 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors, and viruses
CN103687616A (zh) * 2011-07-21 2014-03-26 生物技术工具公司 Dnak制剂
WO2014164727A1 (en) 2013-03-12 2014-10-09 Wisconsin Alumni Research Foundation A method of treating fungal infection
RU2537233C2 (ru) * 2013-03-26 2014-12-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кабардино-Балкарский государственный университет им. Х.М. Бербекова" (КБГУ) Применение комплекса антиоксидантных витаминов и аминокислот в качестве дополнения к стандартным методам терапии и способ лечения папилломавирус-ассоциированных предраковых заболеваний шейки матки и профилактики канцерогенеза при папилломавирусной инфекции
RU2695653C2 (ru) 2013-10-04 2019-07-25 Пин Фарма, Инк. Иммуностимулирующие полипептидные производные тат вич для применения в лечении рака
FR3011850B1 (fr) * 2013-10-15 2018-04-06 Cfl Biotech Vaccin therapeutique contre le cancer a base de proteines de stress rendues immunogenes
MX2017011732A (es) * 2015-03-18 2018-08-15 Omnicyte Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.
WO2017015504A1 (en) 2015-07-21 2017-01-26 Scheibel Steven Frederick Treatment and prevention of anal conditions
CN108484776B (zh) * 2018-03-19 2019-11-05 首都医科大学附属北京朝阳医院 一种融合蛋白、制备方法及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550405A (en) * 1895-11-26 Island
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4906742A (en) 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
AU1548388A (en) 1987-02-02 1988-08-24 Whitehead Institute For Biomedical Research Mycobacterium tuberculosis genes and encoding protein antigens
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
DE68924162T2 (de) 1988-06-15 1996-04-25 Medical Res Council Stressproteine und verwendungen dafür.
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
EP0478664B1 (en) 1989-06-19 2003-09-17 Whitehead Institute For Biomedical Research Vector-mediated genomic insertion and expression of dna in bcg
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
DK0556248T3 (da) 1990-11-08 1997-10-27 Univ London Mycobacterium som adjuvans til antigener
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5580563A (en) 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
GB9211736D0 (en) 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5736146A (en) 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
JP2541081B2 (ja) * 1992-08-28 1996-10-09 日本電気株式会社 バイオセンサ及びバイオセンサの製造・使用方法
CA2164298A1 (en) 1993-06-04 1994-12-22 Richard A. Young Stress proteins and uses therefor
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
IL109790A0 (en) * 1994-05-25 1994-08-26 Yeda Res & Dev Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
EP0888053A4 (en) * 1995-08-18 2002-07-31 Sloan Kettering Inst Cancer METHOD FOR TREATING CANCER AND INFECTIOUS DISEASES AND COMPOSITIONS THAT CAN BE USED THEREFOR
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
EP0851765A4 (en) 1995-09-13 2000-01-19 Univ Fordham THERAPEUTIC AND PROPHYLACTIC PROCESSES THAT USE HEAT SHOCK PROTEINS
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
ES2258796T3 (es) 1996-11-26 2006-09-01 Stressgen Biotechnologies Corporation Proteinas de fusion que contienen proteinas de estres para inducir respuestas inmunitarias.
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
EP1047451A1 (en) 1997-02-18 2000-11-02 Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
PT1336621E (pt) * 1997-08-05 2006-08-31 Stressgen Biotechnologies Corp Respostas imunitarias contra antigenios dos vph, suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector de expressao com aptidao para a expressao destas proteinas
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
EP1196772A2 (en) * 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro

Also Published As

Publication number Publication date
US20030148456A1 (en) 2003-08-07
US20050037017A1 (en) 2005-02-17
DE69834671T2 (de) 2007-05-10
CN1915425A (zh) 2007-02-21
US7262014B2 (en) 2007-08-28
US6524825B1 (en) 2003-02-25
ATE231917T1 (de) 2003-02-15
US20080050399A1 (en) 2008-02-28
KR100843109B1 (ko) 2008-07-02
JP2006001939A (ja) 2006-01-05
CA2298840A1 (en) 1999-02-18
JP2001512749A (ja) 2001-08-28
PL338478A1 (en) 2000-11-06
PT1002110E (pt) 2003-06-30
WO1999007860A1 (en) 1999-02-18
DE69811087D1 (de) 2003-03-06
EP1002110B1 (en) 2003-01-29
JP4198315B2 (ja) 2008-12-17
BR9812272A (pt) 2000-07-18
KR20010022637A (ko) 2001-03-26
HUP0003601A2 (hu) 2001-02-28
KR20060111731A (ko) 2006-10-27
CN1680451A (zh) 2005-10-12
HK1058367A1 (en) 2004-05-14
DK1002110T3 (da) 2003-05-26
US6900035B2 (en) 2005-05-31
HK1028981A1 (en) 2001-03-16
ATE327259T1 (de) 2006-06-15
DE69811087T2 (de) 2003-05-22
ES2266652T3 (es) 2007-03-01
NZ502568A (en) 2003-01-31
NZ522653A (en) 2005-03-24
ES2191929T3 (es) 2003-09-16
EP1002110A1 (en) 2000-05-24
HUP0003601A3 (en) 2003-03-28
AU6492498A (en) 1999-03-01
DE69834671D1 (de) 2006-06-29
NZ538399A (en) 2007-05-31
CN100489105C (zh) 2009-05-20
IL134341A0 (en) 2001-04-30
EP1002110B2 (en) 2009-07-29
CN1270635A (zh) 2000-10-18
PL196805B1 (pl) 2008-02-29

Similar Documents

Publication Publication Date Title
PT1336621E (pt) Respostas imunitarias contra antigenios dos vph, suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector de expressao com aptidao para a expressao destas proteinas
MA24638A1 (fr) Vaccin
DK2928491T3 (en) FUSION PROTEINS TO USE AS IMMUNOGENEOUS AMPLIFIERS FOR INduction OF ANTIGEN-SPECIFIC T-CELL RESPONSES
BR9814487A (pt) "vacina"
WO2002080851A3 (en) Chimeric vaccines
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
SG160336A1 (en) Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
WO2005081716A3 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
EA200300640A1 (ru) Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
Shen et al. Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact
Brulet et al. DNA vaccine encoding endosome‐targeted human papillomavirus type 16 E7 protein generates CD4+ T cell‐dependent protection
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
ATE374244T1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
EP1336621A3 (en) Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
DK0952771T3 (da) Hidtil ukendte saponinpræparater og anvendelser deraf
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
Tang et al. Conjugation with 8-arm PEG and CRM197 enhances the immunogenicity of SARS-CoV-2 ORF8 protein
NZ334582A (en) Polyprotein construct of a papillomavirus